<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03232983</url>
  </required_header>
  <id_info>
    <org_study_id>16639</org_study_id>
    <secondary_id>I8B-MC-ITRT</secondary_id>
    <nct_id>NCT03232983</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants</brief_title>
  <official_title>Effect of Injection Site on the Relative and Absolute Bioavailability of Single Dose of LY900014 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood
      sugar. It is administered by injection into the vein and under the skin of the abdomen, thigh
      and arm.

      The study will be conducted in healthy people to investigate the effect of different
      injection sites on the amount of insulin lispro in the bloodstream.

      Side effects and tolerability will be documented. The study will last for about 10 weeks for
      each participant, including screening and follow up. Screening is required within 28 days
      prior to entering the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Actual">November 9, 2017</completion_date>
  <primary_completion_date type="Actual">November 9, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Insulin Lispro Area under the concentration versus time curve (AUC) following LY900014 administration</measure>
    <time_frame>Predose through 10 hours postdose on day 1 in each study arm</time_frame>
    <description>Pharmacokinetics: Insulin Lispro Area Under the Concentration Curve From Time Zero to 10 hours post dose [AUC(0-10h)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>Predose through 10 hours postdose on day 1 in each study arm</time_frame>
    <description>Glucodynamics: Total Amount of Glucose Infused (Gtot)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY900014 (SC Abdomen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY900014 administered subcutaneously (SC) into the abdomen in one period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 (SC Thigh)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY900014 administered SC into the thigh in one period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 (SC Arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY900014 administered SC into the arm in one period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 (IV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of LY900014 administered intravenously (IV) in one period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014 (SC)</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014 (SC Abdomen)</arm_group_label>
    <arm_group_label>LY900014 (SC Thigh)</arm_group_label>
    <arm_group_label>LY900014 (SC Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014 (IV)</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY900014 (IV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy male or a female (not pregnant and agreeable to take birth control
             measures until study completion)

          -  Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/mÂ²)

          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine
             laboratory test results that are acceptable for the study

          -  Are nonsmokers, have not smoked for at least 6 months prior to entering the study

        Exclusion Criteria:

          -  Are currently participating in or completed a clinical trial within the last 30 days
             or any other type of medical research judged to be incompatible with this study

          -  Have previously participated or withdrawn from this study

          -  Had blood loss of more than 450 milliliters (mL) within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

